Akebia Therapeutics, Inc. AKBA R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.akebia.com

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Market & Price

Market Cap

$273.62M

Current Price

$1.02

High / Low (52W)

$4.01 / $0.90

Beta

0.35

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$0.10

Price to Book

10.00

P/S

1.18

EV/EBITDA

25.43

Dividend Yield

Profitability & Returns

ROCE

9.58%

ROE

-78.95%

ROA

2.02%

Profit Margin

-8.83%

Op Margin

-2.76%

EPS (Latest Qtr)

$-0.03

EPS (TTM)

$-0.08

Balance Sheet & Liquidity

Debt/Equity

7.22

Quick Ratio

1.29

Current Ratio

1.40

Debt

$197.52M

Total Assets

$376.56M

Current Assets

$252.96M

Working Capital

$90.02M

Ownership

Promoter Holding

4.00%

Chg in Prom Hold

0.00%

FII / Inst Holding

42.12%

Chg in FII Hold

0.00%

Financial Snapshot

Enterprise Value

$308.50M

Total Revenue (TTM)

$232.40M

EBITDA

$12.13M

Free Cash Flow

$65.81M

Operating Cash Flow

$60.37M

Shares Outstanding

268.26M

Gross Margin

81.94%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-6.88%

Profit 5Y

31.44%

Revenue (YoY)

-6.60%

Earnings (YoY)

PROS

Profit CAGR of 31.4% over 5 years.
Generates positive free cash flow.

CONS

Revenue declined at -6.9% CAGR over 5 years.
Trading 74.6% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	AKBA Akebia Therapeutics, Inc. R2K	1.02	-	$273.62M	-	9.58%	-78.95%	-6.88%	31.44%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	28.52M	41.28M	-	45.93M	48.79M	53.17M	-	72.67M	100.80M	91.98M	-	88.48M	90.14M	59.99M	-	52.30M	52.91M	48.76M	61.70M	126.36M	48.71M	40.01M	56.38M	42.05M	32.61M	43.65M	-	-	57.34M	62.47M	58.77M	57.62M	53.54M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.62M	9.92M	9.38M	12.54M	12.29M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49.71M	52.55M	49.38M	45.09M	41.25M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	36.20M	38.46M	44.93M	53.64M	45.95M
Operating Income	-19.68M	-20.05M	-26.05M	-36.19M	-36.18M	-38.04M	-44.97M	-22.14M	-24.18M	14.61M	-24.50M	-35.66M	-27.84M	-90.16M	-75.97M	-59.52M	-55.91M	-94.89M	-59.12M	-173.82M	-58.09M	-85.40M	-64.94M	-79.34M	-54.89M	-59.58M	34.08M	-50.41M	-25.60M	-9.00M	-13.04M	-14.94M	-8.72M	-	-	13.51M	14.09M	4.45M	-8.55M	-4.70M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.20M	7.40M	6.22M	-6.09M	-3.91M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.77M	6.83M	4.75M	4.83M	4.69M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.11M	247.00K	1.16M	-11.23M	-8.93M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	615.00K	1.01M	126.00K
Net Income	-19.48M	-19.86M	-25.80M	-35.78M	-36.31M	-37.86M	-44.54M	-21.52M	-23.13M	15.52M	-23.42M	-34.07M	-26.05M	-60.05M	-72.42M	-58.17M	-54.59M	-94.48M	-60.75M	-175.75M	-59.96M	-87.00M	-69.58M	-83.04M	-59.54M	-63.51M	29.45M	-54.10M	-26.88M	-11.17M	-14.49M	-17.98M	-8.58M	-	-	6.11M	247.00K	540.00K	-12.24M	-9.05M
Diluted EPS	-	-	-	-	-	-	-1.15	-0.53	-0.49	0.31	-	-	-	-	-	-	-	-	-	-1.28	-0.42	-	-0.45	-0.51	-0.34	-0.35	0.15	-0.29	-0.15	-0.06	-0.08	-0.09	-0.04	-	-	0.03	0.00	0.00	-0.05	-0.03
R&D Expense	15.60M	-	20.23M	30.88M	31.24M	-	60.05M	43.75M	58.71M	-	61.40M	71.92M	70.63M	-	82.35M	85.69M	74.51M	-	81.23M	52.82M	46.86M	-	40.61M	37.21M	40.47M	43.83M	26.03M	28.03M	19.69M	20.20M	13.33M	9.73M	7.65M	8.49M	-	9.75M	11.01M	14.94M	-	14.81M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	1.53M	181.23M	207.74M	335.00M	295.31M	-	292.48M	194.62M	160.18M	236.20M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	85.57M	74.15M	63.18M	39.46M
Gross Profit	-	-	-	-	-	-	-	-	-	-	206.92M	120.47M	97.00M	196.73M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	271.76M	166.55M	147.42M	173.24M
Operating Income	-8.52M	-15.93M	-37.94M	-61.51M	-136.46M	-76.67M	-178.16M	-286.29M	-376.44M	-	-64.85M	-46.08M	-50.41M	23.50M
EBITDA	-	-	-	-	-	-	-	-	-	-	-40.84M	-8.27M	-13.72M	21.73M
Interest Expense	-	-	-	-	-	-	-	-	-	-	15.69M	6.03M	18.18M	24.18M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-94.23M	-51.92M	-69.41M	-3.72M
Tax Provision	-	-	-	-	-	-	-	-	-	-	0	0	0	1.62M
Net Income	-8.20M	-13.17M	-37.03M	-60.72M	-135.75M	-73.67M	-143.59M	-279.66M	-383.46M	-	-94.23M	-51.92M	-69.41M	-5.34M
Diluted EPS	-	-	-	-	-	-	-	-2.36	-2.77	-	-0.51	-0.28	-0.33	-0.02
R&D Expense	5.63M	8.90M	23.26M	43.02M	115.78M	230.89M	291.01M	322.97M	218.49M	147.85M	129.99M	63.08M	37.65M	62.36M

Compounded Sales Growth

5 Years:	-6.88%
1 Year:	-6.60%

Compounded Profit Growth

5 Years:	31.44%
1 Year:	-

Stock Price Performance

1 Year:	-66.34%
6 Months:	-35.03%
3 Months:	-22.14%
1 Month:	-25.00%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	34.66M	111.00M	142.94M	300.22M	364.25M	996.54M	771.20M	644.14M	-	356.05M	241.70M	220.67M	376.56M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	185.18M	118.15M	113.83M	252.96M
Cash & Equivalents	5.01M	1.64M	21.21M	32.78M	49.78M	187.34M	70.16M	104.64M	147.45M	228.70M	-	90.47M	42.92M	51.87M	184.84M
Inventory	-	-	-	-	-	-	-	-	-	-	-	21.57M	15.69M	16.24M	15.61M
Receivables	-	-	-	-	-	-	-	-	-	-	-	40.28M	39.29M	34.37M	47.03M
Total Liabilities	-	-	3.91M	6.92M	11.94M	232.10M	241.67M	360.61M	376.44M	396.52M	-	350.82M	272.29M	269.86M	343.95M
Current Liabilities	-	-	3.90M	6.88M	11.87M	114.27M	141.11M	265.69M	208.12M	187.15M	-	129.54M	99.87M	80.91M	162.94M
Long Term Debt	-	-	-	-	-	-	-	-	75.81M	96.38M	-	34.08M	17.18M	38.69M	48.25M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	99.78M	48.12M	47.64M	51.80M
Total Equity	-48.19M	-59.59M	-127.07M	104.08M	131.00M	68.12M	122.57M	635.93M	394.76M	247.62M	-	5.23M	-30.58M	-49.19M	32.61M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	184.14M	194.58M	224.85M	265.42M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	57.91M	-56.16M	-97.49M	-257.44M	-110.39M	-	-73.15M	-23.38M	-40.66M	67.99M
Investing Cash Flow	-	-	-	12.71M	-177.26M	36.59M	211.18M	-40.00M	-	-114.00K	0	-33.00K	-7.93M
Financing Cash Flow	-	-	-	66.95M	116.24M	96.56M	88.97M	231.72M	-	14.60M	-25.21M	49.66M	72.93M
Capital Expenditure	-19.00K	-229.00K	-414.00K	-2.66M	-1.62M	-1.61M	-6.66M	-317.00K	-59.00K	-114.00K	-	-33.00K	-8.10M
Free Cash Flow	-	-	-	55.24M	-57.78M	-99.10M	-264.10M	-110.70M	-	-73.27M	-23.38M	-40.69M	59.89M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-58.67M	-48.59M	8.97M	132.99M
Share Buybacks	-	162.00K	-	-	-	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	70.7%	61.9%	60.6%	83.3%
Operating Margin %	-	-	-	-	-8,889.9%	-42.3%	-85.8%	-85.5%	-127.5%	-	-22.2%	-23.7%	-31.5%	9.9%
Net Margin %	-	-	-	-	-8,843.5%	-40.7%	-69.1%	-83.5%	-129.9%	-	-32.2%	-26.7%	-43.3%	-2.3%
ROE %	13.8%	10.4%	-35.6%	-46.3%	-199.3%	-60.1%	-22.6%	-70.8%	-154.9%	-	-1,801.6%	169.8%	141.1%	-16.4%
ROCE %	-	-51.8%	-36.4%	-46.9%	-73.4%	-34.4%	-24.4%	-50.8%	-82.4%	-	-28.6%	-32.5%	-36.1%	11.0%

Shareholding Pattern

Insiders

4.00%

Institutions

42.12%

Public Float

43.87%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	6.97%	18.69M	$19.07M
2	State Street Corporation	4.33%	11.61M	$11.85M
3	Vanguard Capital Management LLC	4.16%	11.17M	$11.39M
4	Geode Capital Management, LLC	2.41%	6.45M	$6.58M
5	Goldman Sachs Group Inc	1.34%	3.60M	$3.67M
6	Citigroup Inc.	1.06%	2.85M	$2.91M
7	Bank of America Corporation	1.03%	2.76M	$2.82M
8	Qube Research & Technologies Ltd	0.89%	2.40M	$2.44M
9	Millennium Management Llc	0.89%	2.38M	$2.43M
10	Vanguard Portfolio Management LLC	0.83%	2.22M	$2.26M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AKBA

No recent headlines available.

AKBA · Healthcare